Generic Statin Pricing: What Every Patient Should Know in 2026

How Much Do Generic Statins Actually Cost?

Generic statins are among the least expensive prescription drugs in the United States. A 30-day supply of atorvastatin 20 mg or simvastatin 20 mg runs between $4 and $15 at major chain pharmacies, and several retailers include these drugs on $4 generic lists [1]. Rosuvastatin, which lost patent protection in 2016, now costs $10 to $30 per month depending on dose and pharmacy.

These prices represent a dramatic drop from peak brand-name costs. When Lipitor (atorvastatin) was still under patent, a monthly supply carried a retail price exceeding $170. The entry of generic manufacturers collapsed that price by more than 90%. According to the FDA's Office of Generic Drugs, generic competition from four or more manufacturers typically drives prices down to 20% of the original brand cost [2].

The 2018 ACC/AHA Cholesterol Clinical Practice Guideline identifies statin therapy as first-line treatment for atherosclerotic cardiovascular disease (ASCVD) risk reduction and notes that "the availability of low-cost generic statins makes this class one of the highest-value interventions in cardiovascular medicine" [3]. That assessment holds in 2026. The Cholesterol Treatment Trialists' Collaboration meta-analysis (N=170,000 across 26 trials) demonstrated that each 1 mmol/L reduction in LDL-C with statin therapy reduces major vascular events by approximately 22% [4].

Statin-by-Statin Price Comparison

Not all generic statins cost the same. Simvastatin and lovastatin, the oldest generics (both off-patent since the mid-2000s), carry the lowest cash prices. Atorvastatin falls in the middle. Rosuvastatin and pitavastatin sit at the higher end.

Here is what to expect for a 30-day supply at cash price without insurance:

Simvastatin 20 mg: $4 to $8. Available on most $4 generic lists. The 4S trial (N=4,444) first proved that simvastatin reduced total mortality by 30% over 5.4 years in patients with coronary heart disease [5].

Atorvastatin 40 mg: $6 to $15. The most widely prescribed statin globally. In the CARDS trial (N=2,838), atorvastatin 10 mg reduced major cardiovascular events by 37% in patients with type 2 diabetes [6].

Rosuvastatin 10 mg: $10 to $30. Often preferred for its potency. The JUPITER trial (N=17,802) showed rosuvastatin 20 mg reduced the combined endpoint of MI, stroke, revascularization, and cardiovascular death by 44% in individuals with elevated hsCRP and LDL-C <130 mg/dL [7].

Pravastatin 40 mg: $8 to $20. Fewer drug interactions due to minimal CYP3A4 metabolism. Often chosen for patients on complex medication regimens.

Pitavastatin 2 mg: $15 to $45. The newest statin to gain generic status (2023). In the REAL-CAD trial (N=13,054), pitavastatin 4 mg reduced the composite cardiovascular endpoint by 19% vs. pitavastatin 1 mg [8].

Lovastatin 20 mg: $4 to $10. The first statin approved by the FDA (1987). Requires administration with food for adequate absorption.

Fluvastatin 40 mg: $15 to $35. Less commonly prescribed but available as a generic extended-release formulation.

Where to Find the Lowest Statin Prices

Pharmacy choice matters more than most patients realize. The same generic atorvastatin 40 mg prescription can range from $4 at Walmart or Costco to $25 at an independent pharmacy without discount programs.

Several options consistently offer the lowest prices. Walmart's $4 Prescriptions program covers simvastatin, lovastatin, and pravastatin at all doses, plus atorvastatin at select strengths [9]. Costco's pharmacy (open to non-members) prices generic statins between $5 and $12 for 30-day supplies. Mark Cuban's Cost Plus Drugs prices atorvastatin 40 mg at approximately $4.20 for a 30-day supply, with transparent markup disclosure.

Discount card programs like GoodRx, RxSaver, and SingleCare can reduce cash prices by 50% to 80% at chain pharmacies. A GoodRx coupon typically brings atorvastatin 20 mg below $8 at CVS or Walgreens.

Dr. Seth Baum, past president of the American Society for Preventive Cardiology, has stated: "Cost should never be the reason a patient stops taking their statin. With generics priced at a few dollars per month, the cost-effectiveness of statin therapy is unmatched in cardiovascular prevention" [10].

For patients with insurance, generic statin copays typically fall between $0 and $10 under most commercial formularies. Medicare Part D plans classified all generic statins as Tier 1 preferred generics, keeping copays at or below $10 for the standard benefit phase as of 2025 [11].

Brand-Name Statins: Are They Ever Worth the Premium?

Only one branded statin retains significant market share: Livalo (pitavastatin). Before generic pitavastatin launched in 2023, Livalo carried a list price of roughly $350 per month. The generic version now costs $15 to $45, making the brand-name product unnecessary for almost all patients.

Combination products remain brand-only in some cases. Caduet (atorvastatin plus amlodipine) still has a list price exceeding $200 per month, but prescribing the two generics separately costs under $15 combined. Vytorin (simvastatin plus ezetimibe) faced the same situation after generic ezetimibe launched; taking the two pills separately costs a fraction of the combination.

The clinical evidence does not support paying more for brand-name formulations. The FDA requires generic drugs to demonstrate bioequivalence, defined as 90% confidence intervals for the area under the curve (AUC) and peak concentration (Cmax) falling within 80% to 125% of the reference product [2]. In practice, the average difference between brand and generic statin blood levels is 3% to 4%, well within normal day-to-day pharmacokinetic variability.

PCSK9 Inhibitor Pricing: A Different Price Category

When generic statins are not enough, clinicians may add PCSK9 inhibitors for patients with familial hypercholesterolemia (FH) or established ASCVD who need additional LDL-C reduction. These biologics occupy a very different cost tier.

Evolocumab (Repatha) carries a current list price of approximately $5,850 per year following Amgen's 2023 price reduction from the original $14,100 annual cost [12]. Alirocumab (Praluent), manufactured by Regeneron and Sanofi, is priced similarly at roughly $5,850 per year. Both are self-injected subcutaneously every two weeks or monthly.

The FOURIER trial (N=27,564) demonstrated that evolocumab added to statin therapy reduced the composite endpoint of cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization by 15% over a median of 2.2 years [13]. LDL-C dropped by 59% from a median baseline of 92 mg/dL.

Insurance coverage for PCSK9 inhibitors requires prior authorization in almost every case. Payers typically require documented statin intolerance (to at least two statins) or inadequate LDL-C response despite maximally tolerated statin therapy plus ezetimibe. Out-of-pocket costs after insurance range from $0 (with manufacturer copay cards for commercially insured patients) to several hundred dollars per month for Medicare beneficiaries who fall into the coverage gap.

Dr. Steven Nissen, Chief Academic Officer of the Heart, Vascular, and Thoracic Institute at Cleveland Clinic, noted in a 2023 editorial: "The PCSK9 inhibitor price reductions have moved these drugs closer to cost-effectiveness thresholds, but they remain 50 to 100 times more expensive than generic statins on an annual basis" [14].

Cost of Inclisiran (Leqvio): The Newest Option

Inclisiran (Leqvio), a small interfering RNA (siRNA) therapy targeting PCSK9, received FDA approval in December 2021. Its mechanism differs from monoclonal antibody PCSK9 inhibitors: inclisiran silences PCSK9 messenger RNA in the liver, reducing production of the protein rather than blocking it in circulation [15].

The dosing schedule is its main practical advantage. After two initial doses (at day 0 and day 90), inclisiran is administered every six months via subcutaneous injection in a healthcare provider's office. The list price is approximately $3,250 per injection, translating to about $6,500 per year for maintenance dosing.

In the pooled analysis of the ORION-10 and ORION-11 trials (combined N=3,178), inclisiran reduced LDL-C by 50% to 52% at day 510 compared to placebo, with effects persisting between the six-month dosing intervals [16]. The ongoing ORION-4 cardiovascular outcomes trial (N=15,000) is expected to report results clarifying whether these LDL-C reductions translate to reduced cardiovascular events.

Because inclisiran is administered in a physician's office, it is billed under Medicare Part B (the medical benefit) rather than Part D (the pharmacy benefit). This distinction has practical cost implications. Under Part B, patients pay 20% coinsurance after meeting the deductible, which can mean out-of-pocket costs of $650 per injection without supplemental coverage. Novartis offers a patient assistance program that can reduce costs to $0 for eligible commercially insured patients.

The Institute for Clinical and Economic Review (ICER) assessed inclisiran's value in 2021 and concluded that the annual net price would need to fall to between $3,600 and $5,000 per year to align with commonly cited willingness-to-pay thresholds of $100,000 to $150,000 per quality-adjusted life year (QALY) [17].

How Insurance and Formulary Tier Affect What You Pay

The true out-of-pocket cost for any cholesterol medication depends heavily on insurance structure. Generic statins sit on Tier 1 of nearly every formulary, resulting in copays of $0 to $10. Some employer-sponsored plans and Affordable Care Act marketplace plans cover generic statins with no copay at all when prescribed for primary prevention, following the USPSTF Grade B recommendation for statin use in adults aged 40 to 75 with at least one cardiovascular risk factor and an estimated 10-year ASCVD risk of 10% or greater [18].

PCSK9 inhibitors and inclisiran land on specialty tiers (Tier 4 or 5), where coinsurance of 25% to 33% is standard. A commercially insured patient without a copay card could face $120 to $160 per month for Repatha or Praluent. Medicare Part D beneficiaries may pay more, particularly during the coverage gap phase, though the Inflation Reduction Act's $2,000 annual out-of-pocket cap (effective 2025) now limits total Part D spending [19].

Manufacturer copay assistance programs significantly change the math for commercially insured patients. Amgen's Repatha copay card covers up to $150 per month, potentially bringing the patient cost to $0. Novartis offers a similar program for Leqvio. These programs do not apply to government insurance (Medicare, Medicaid, Tricare).

Strategies to Reduce Your Cholesterol Medication Costs

Patients paying out of pocket for statins have several concrete options. First, ask the prescriber about simvastatin or lovastatin if the clinical situation allows. These are the cheapest generics available. Second, compare prices across at least three pharmacies using GoodRx, RxSaver, or the Medicare Plan Finder tool. Price differences of 300% for the same medication at pharmacies within a few miles of each other are common.

Pill splitting is another established cost-reduction method for statins. Atorvastatin and simvastatin tablets are scored and can be split safely. Purchasing a higher-strength tablet and splitting it can cut costs by nearly half, since statin pricing is often flat across strengths [20]. The 2018 ACC/AHA guideline does not explicitly address pill splitting, but the practice is well-documented in cost-effectiveness literature.

90-day mail-order prescriptions often carry lower per-unit costs than 30-day retail fills. Express Scripts, CVS Caremark, and OptumRx typically price 90-day generic statin supplies at two to 2.5 times the 30-day copay rather than three times.

For patients who require PCSK9 inhibitors but face high copays, working with the prescriber's office to complete prior authorization paperwork thoroughly (including documentation of statin intolerance or FH diagnosis) increases the likelihood of full coverage. Appeals of initial denials succeed approximately 50% to 60% of the time when supported by appropriate clinical documentation.

Generic Statins vs. Newer Agents: Cost per LDL Point Reduced

Evaluating cost-effectiveness requires looking beyond the sticker price. Generic atorvastatin 80 mg reduces LDL-C by approximately 50%, translating to a cost of roughly $0.20 to $0.30 per month per percentage point of LDL reduction. Rosuvastatin 40 mg achieves up to 55% LDL-C reduction at $0.50 to $0.90 per percentage point.

PCSK9 inhibitors reduce LDL-C by 50% to 60% on top of statin therapy. At $487 per month ($5,850/year), the cost per percentage point of additional LDL-C reduction runs approximately $8 to $10 per month. Inclisiran achieves similar LDL-C reductions at a slightly higher annual cost but with only two injections per year.

A 2022 analysis published in JAMA Cardiology estimated that generic high-intensity statin therapy costs approximately $900 per QALY gained, while PCSK9 inhibitors at their reduced price of $5,850 per year cost approximately $85,000 per QALY [21]. Both fall under commonly accepted cost-effectiveness thresholds, but the difference is striking: generic statins remain roughly 90 times more cost-effective per QALY.

The 2018 ACC/AHA guideline recommends initiating maximally tolerated statin therapy before considering add-on agents, a recommendation driven as much by cost-effectiveness data as by the depth of outcomes evidence supporting statins over newer drug classes [3].